HomeCompareNWSAL vs JNJ

NWSAL vs JNJ: Dividend Comparison 2026

NWSAL yields 0.74% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.9K in total portfolio value· pulled ahead in Year 7
10 years
NWSAL
NWSAL
● Live price
0.74%
Share price
$26.80
Annual div
$0.20
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$686.69
Full NWSAL calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NWSAL vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNWSALJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NWSAL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NWSAL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NWSAL
Annual income on $10K today (after 15% tax)
$63.32/yr
After 10yr DRIP, annual income (after tax)
$583.69/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,402.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NWSAL + JNJ for your $10,000?

NWSAL: 50%JNJ: 50%
100% JNJ50/50100% NWSAL
Portfolio after 10yr
$26.8K
Annual income
$2,688.05/yr
Blended yield
10.02%
📊

Analyst Conviction Gap

Where Wall Street is split right now

NWSAL
Analyst Ratings
19
Buy
5
Hold
2
Sell
Consensus: Buy
Altman Z
2.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NWSAL buys
0
JNJ buys
0
No recent congressional trades found for NWSAL or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNWSALJNJ
Forward yield0.74%2.13%
Annual dividend / share$0.20$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.1%28%
Portfolio after 10y$23.4K$30.3K
Annual income after 10y$686.69$4,689.40
Total dividends collected$3.0K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NWSAL vs JNJ ($10,000, DRIP)

YearNWSAL PortfolioNWSAL Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,792$91.70$10,592$272.30+$200.00NWSAL
2$11,661$113.86$11,289$357.73+$372.00NWSAL
3$12,619$141.54$12,123$472.89+$496.00NWSAL
4$13,678$176.21$13,141$629.86+$537.00NWSAL
5$14,856$219.75$14,408$846.81+$448.00NWSAL
6$16,170$274.57$16,021$1,151.60+$149.00NWSAL
7← crossover$17,646$343.83$18,122$1,588.22$476.00JNJ
8$19,313$431.67$20,930$2,228.20$1.6KJNJ
9$21,208$543.54$24,792$3,191.91$3.6KJNJ
10$23,379$686.69$30,274$4,689.40$6.9KJNJ

NWSAL vs JNJ: Complete Analysis 2026

NWSALStock

News Corporation, a media and information services company, creates and distributes authoritative and engaging content, and other products and services for consumers and businesses worldwide. It operates in six segments: Digital Real Estate Services, Subscription Video Services, Dow Jones, Book Publishing, News Media, and Other. The company distributes content and data products, including The Wall Street Journal, Barron's, MarketWatch, Investor's Business Daily, Factiva, Dow Jones Risk & Compliance, Dow Jones Newswires, and OPIS through various media channels, such as newspapers, newswires, websites, mobile apps, newsletters, magazines, proprietary databases, live journalism, video, and podcasts. It also owns and operates daily, Sunday, weekly, and bi-weekly newspapers comprising The Australian, The Weekend Australian, The Daily Telegraph, The Sunday Telegraph, Herald Sun, Sunday Herald Sun, The Courier Mail, The Sunday Mail, The Advertiser, Sunday Mail, The Sun, The Sun on Sunday, The Times, The Sunday Times, and New York Post, as well as digital mastheads and other websites. In addition, the company publishes general fiction, nonfiction, children's, and religious books; provides sports, entertainment, and news services to pay-TV and streaming subscribers, and other commercial licensees through cable, satellite, and internet distribution; and broadcasts rights to live sporting events. Further, it offers property and property-related advertising and services on its websites and mobile applications; online real estate services; and financial services. The company was founded in 2012 and is headquartered in New York, New York.

Full NWSAL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NWSAL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NWSAL vs SCHDNWSAL vs JEPINWSAL vs ONWSAL vs KONWSAL vs MAINNWSAL vs ABBVNWSAL vs MRKNWSAL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.